A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

This study is for adults aged 40 years or older. You must have at least one close family member (like a parent, sibling, or child) who has been diagnosed with pulmonary fibrosis or other related lung scarring conditions. Importantly, a special lung scan (HRCT) must show early changes in your lungs, known as interstitial lung abnormalities, which cover at least 5% of a single lung section.

There are also some criteria that would mean you couldn't join. For example, if you already have a diagnosed lung scarring condition that needs treatment, or if your lung function tests fall below certain levels. Also, if you have other conditions known to cause lung scarring, such as certain connective tissue diseases, or if you've previously taken nerandomilast or other specific lung fibrosis medicines, you wouldn't be able to participate.

If you decide to take part, you'll be in the study for about 2 to 3 years. You'll be asked to take a tablet twice a day – either the study drug, nerandomilast, or a placebo (dummy pill). There's a 3 out of 5 chance you'll receive nerandomilast. You won't know which one you're taking, and neither will your local study team.

Over the study period, you'll have several visits to the study clinic. In the first two years, these visits will be more frequent, happening about every three months. After that, they'll be every six months. In the third year, you'll also have phone conversations with the study team every three months to check in on how you're doing. During these visits, doctors will regularly check your lung function with breathing tests and take chest scans to see if the treatment is having an effect. They will also keep a close eye on your general health and any side effects you might experience.